Pomerantz Law Firm Investigates Securities Fraud Claims Against Organogenesis Holdings Inc.

Investor Alert: Investigation into Organogenesis Holdings Inc.

On October 8, 2025, Pomerantz LLP announced it is actively investigating claims from investors of Organogenesis Holdings Inc. (NASDAQ: ORGO). This investigation seeks to determine if the firm or its leadership engaged in any form of securities fraud or improper business practices.

Investors who believe they may be affected are encouraged to make contact with Danielle Peyton at Pomerantz. This inquiry comes in the aftermath of a significant announcement made by Organogenesis on September 25, 2025, regarding the completion of a Phase 3 trial for its cryopreserved amniotic suspension allograft, ReNu. The trial reportedly did not meet its primary endpoint, as it failed to exhibit a statistically significant change in pain reduction.

In following the release of this information, Organogenesis's stock suffered considerably, dropping $0.58 per share or over 12% within a single trading day. The current status of the company's future strategy includes plans to engage with the U.S. Food and Drug Administration (FDA) by the end of October to explore routes for submitting a Biologics License Application (BLA), possibly leveraging efficacy data from both Phase 3 studies in seeking approval.

Pomerantz LLP is located in several major cities across the globe, including New York, Chicago, London, and Paris. Renowned for its success in corporate class litigation, Pomerantz has a rich history in fighting for the rights of investors against corporate misconduct and securities fraud, a foundation established by its late founder, Abraham L. Pomerantz.

The firm has successfully recovered substantial monetary damages on behalf of various class members in multiple cases over its extensive operations that have spanned over eight decades. Investors of Organogenesis are strongly advised to reach out to Pomerantz for support in understanding any potential legal options available concerning their investments.

Pomerantz's commitment to advocacy in the face of unfair practices can be a reliable source for investors feeling uncertain about their positions with Organogenesis Holdings Inc. Those interested in exploring their rights in this matter should not hesitate to make contact directly, as it could lead to important legal developments and insights into the proceedings moving forward.

For more detailed assistance, investors are advised to contact Pomerantz. Their years of experience in handling such matters could be pivotal in determining the next steps regarding potential securities fraud litigation relevant to Organogenesis Holdings Inc.